SymBio`s Expanded Access Policy

What is SymBio's expanded access policy?

Intravenous brincidofovir (IV BCV) is not currently approved by the United States Food and Drug Administration (FDA) nor any other regulator for any indication. SymBio is committed to making IV BCV available to patients in need as soon as possible through expedited clinical development. We are currently conducting a global Phase 3 clinical trial to evaluate the efficacy and safety of IV BCV for treatment of adenovirus infection after hematopoietic stem cell transplantation (ClinicalTrials.gov Identifier: NCT07387367). IV BCV is currently only available through participation in the clinical trial and is not separately available through an expanded access or compassionate use program at this time.